The reinvention of Baxter goes on. The company that in the early 2000s was a permanent fixture among the global top 10 medtechs, focused on peritoneal and hemodialysis, will transform further in 2025 after spinning off renal care in 2024.
MTI100 - Into 2025: Investor Optimism Ahead As Big Medtech Proves ‘It’s All About Value’
Things Can Only Get Better? Medtechs Refocus On Core Drivers, Express Nuanced Views About AI
Pressure to exploit connected care functionality is accelerating the shift in care delivery away from the inpatient setting. Medtechs are reshaping to maximize faster-growth opportunities.
More from Company Rankings
• By
Pressure to exploit connected care functionality is accelerating the shift in care delivery away from the inpatient setting. Medtechs are reshaping to maximize faster-growth opportunities.
The Top 100 ranking of global medtechs by revenues for 2023 illustrated how the leaders continue to tailor innovation to users and patients according to market trends while driving portfolio management for growth.
• By
Top 100 publicly listed medtech companies ranked by global revenues, and listings for the top cardiology, orthopedic, IVD and imaging performers based on 2023 or 2023-24 revenues, are now available from Medtech Insight.
More from Medtech Insight
• By
Cambridge, UK-based breath biopsy company Owlstone Medical will apply its volatile organic compound analysis platform in an attempt to develop a test for the identification and monitoring of pseudomonas aeruginosa in patients with cystic fibrosis.
The Doctor Patient Forum says the US FDA should regulate a scoring platform from Bamboo Health intended to help clinicians calculate risk for opioid abuse as a medical device to ensure patient safety.
• By
The urine-based GAGome test showed promise in the first clinical results from the international AURORAX-0087A, in the largest study conducted on clear cell renal cell carcinoma, the most common type of kidney cancer.